3 results
To compare the effect of paclitaxel plus MORAb-003 to paclitaxel plus placebo on progression free survival (PFS) as determined by RECIST in subjects who are in a first platinum-resistant or refractory relapse of ovarian cancer.
- to evaluate the FVIIa activity PK of 2 CSL689 dose levels in subjects with congenital FVII deficiency- to determine the PK characteristics of FVIIa activity of CSL689- to evaluate the safety and tolerability of intravenous administration of CSL689
The goals of our study are: 1) to evaluate the performance of a single hs-troponin measurement using universal and sex-specific cut-off values; 2) to evaluate whether embedding hs-troponin in a clinical risk score (HEART, INTERCHEST, Marburg Heart…